Skip to main content

MARSHALL WACE, LLP

Position in VTRS — Viatris Inc

CIK 1318757 LONDON, X0

Position in VTRS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$126,316,026
+$121,300,432 QoQ
Shares Held
9,349,817
+2220.9% QoQ
Ownership
0.803%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Dec 2020
15 quarters on record
Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Common Shares in VTRS Over Time

Shares Held

Position Value (USD)

Derivatives in VTRS

reported options exposure · as of Mar 31, 2026
CallValue
$40,530
CallShares
3,000
PutValue
$10,808
PutShares
800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $558,161,566 across 33 Drug Manufacturers - Specialty & Generic names. VTRS ranks #1 (22.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VTRS
Viatris Inc
This page
9,349,817 $126,316,026

All Filings in VTRS

Export CSV
18 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $126,316,026 9,349,817
2026-03-31 $10,808 800
2026-03-31 $40,530 3,000
2025-12-31 $5,015,594 402,859
2025-09-30 $3,135,062 316,673
2025-06-30 $5,183,480 580,457
2025-03-31 $2,259,844 259,454
2024-12-31 $14,587,813 1,171,712
2024-09-30 $599,273 51,617
2024-06-30 $11,704,703 1,101,101
2023-03-31 $3,494,801 363,285
2022-09-30 $7,215,016 846,833
2022-06-30 $4,113,767 392,910
2022-03-31 $88,021,113 8,090,176
2021-12-31 $32,852,192 2,428,100
2021-09-30 $8,103,685 598,058
2021-09-30 $201,895 14,900
2020-12-31 $877,275 46,813